Trial Profile
A Phase 2, Randomized, Double-Blinded Study of the Safety and Efficacy of Elvitegravir/Emtricitabine/Tenofovir Disoproxil Fumarate/GS-9350 Versus Atripla (R) (Efavirenz 600 mg/Emtricitabine 200 mg/Tenofovir Disoproxil Fumarate 300 mg) in HIV-1 Infected, Antiretroviral Treatment-Naive Adults
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 17 Sep 2021
Price :
$35
*
At a glance
- Drugs Elvitegravir/emtricitabine/tenofovir disoproxil fumarate/cobicistat (Primary) ; Efavirenz/emtricitabine/tenofovir-disoproxil-fumarate
- Indications HIV-1 infections
- Focus Therapeutic Use
- Sponsors Gilead Sciences
- 19 Mar 2014 Status changed from active, no longer recruiting to completed, as per ClinicalTrials.gov record.
- 06 Nov 2013 Planned end date changed from 1 Dec 2012 to 1 Nov 2013 as reported by ClinicalTrials.gov.
- 13 Sep 2013 Results for the open-label extension presented at the 53rd Interscience Conference on Antimicrobial Agents and Chemotherapy.